Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: A model based on the CLARITY trial

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 641-651

  Thurston, S J ^a   Heeg, B ^b   De Charro, F ^b   Van Hout, B ^a,c  

^a PHARMERIT INTERNATIONAL   (United States)

^b PHARMERIT INTERNATIONAL   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Clopidogrel; Cost; Decision model; Effectiveness; Segment elevation myocardial infarction; ST

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION TREE; DRUG COST; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; ST SEGMENT ELEVATION; STATISTICAL MODEL; STROKE; SURVIVAL;

ASPIRIN; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 76949103460     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903529267     Document Type: Article

References (36)

1. Mehta SR, Yusuf S, Peters RGJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
2. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
4. Sabatine MS, Cannon CP, Gibson M, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
5. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621
6. Berg J, Lindgren P, Spiesser J, et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther 2007;29:1184-1202
7. Swedish National Board of Health and Welfare. Hospital discharge register 1995-2003. 2003
8. Swedish National Board of Health and Welfare. Cause of death register 1995-2003. 2003
9. World Health Organization. Highlights on health in Sweden. 2004
10. World Health Organization. Highlights on health in the Netherlands. 2004
11. Centraal Bureau voor de Statistiek. Time series labour force by sex. 2006
12. Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, et al. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2004;14:435-443
13. Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001;55:51-69
14. Hiatt MD. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: a decision analysis. Cardiology 1999;91:243-249
15. Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-1424
16. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-165
17. Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999;246:309-316
18. Lee TT, Solomon N, Heidenreich PA, et al. A cost-effectiveness of screening for carotoid stenosis in asymptomatic persons. Ann Intern Med 1997; 126:337-346
19. College voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen, 1999
20. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
21. College voor Zorgverzekeringen. Medicijnkosten. 2006
22. Fox KM and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
23. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-659
24. College van Toezicht Sociale Verzekeringen. Bestanden ziekteverzium uit de diagnosestatistiek ziekengeldverzekering 1994. 1996
25. van Exel NJA, Koopmanschap MA, van Wijngaarden JDH, et al. Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc 2003;1
26. Dutch Healthcare Insurance Board. Manual for costing research, unit costs and tariffs medical procedures. 2006
27. CAPRIE Steering Committee. A randomised, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348:1329-1339
28. Steinhubl SR, Berger PB, Mann JT, et al. Clopidogrel for the reduction of events during observation. JAMA 2002;288:2411-2420
29. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717
30. Zhang Z, Kolm P, Mosse F, et al. Long-term cost-effectiveness of clopidogrel in STEMI patients. Int J Cardiol 2008;135:353-360
31. Harland JO, Unwin N, Bhopal RS, et al. Low levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population. J Epidemiol Community Health 1997;51:636-642
32. Woo KS, Chook P, Young RP, et al. New risk factors for coronary heart disease in Asia. Int J Cardiol 1997;62:S39-S42
33. Brü ggenjü rgen B, Lindgren P, Ehlken B, et al. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. Eur J Health Econ 2007;8:51-57
34. Lamy A, Jö nsson B, Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil 2004;11:460-465 (Pubitemid 40096846)
35. Lindgren P, Jönsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med 2004;255:562-570 (Pubitemid 38534869)
36. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008;24:2089-2101